SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases,

– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – –  Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 –   – Initiated a third Phase 2 of PRA023 into SSc-ILD, demonstrating pipeline-in-a-product candidate

- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3 r d - - Oral Presentation on ARTEMIS-UC Phase 2 primary and secondary endpoint data from Cohort 1 to be presented on March 4 th - SAN DIEGO, Feb.

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc.  (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p

- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position provides runway into mid-2024 - SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc.

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment